<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569451</url>
  </required_header>
  <id_info>
    <org_study_id>10-1143</org_study_id>
    <nct_id>NCT01569451</nct_id>
  </id_info>
  <brief_title>Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate</brief_title>
  <acronym>GATEWAYII</acronym>
  <official_title>A Double Blinded, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rocky Mountain MS Research Group, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is (1) to determine if rituximab induction therapy followed by
      glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by
      GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple
      sclerosis (RMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, active comparator; single-center study involving up to 90 subjects
      with qualifying CIS or RMS. Subjects who are not screen-failures must be randomized within 60
      days of signing the informed consent document. Subjects who are not randomized within these
      60 days must be re-screened for enrollment into the study. Patients will be stratified based
      on their diagnosis of CIS or RMS (Relapsing Remitting or Secondary Progressive) and then
      randomly assigned at a 1:1 ratio to either rituximab induction followed by standard GA
      therapy (R-GA arm), or placebo induction followed by standard GA therapy (GA arm). Subjects
      will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline)
      on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On
      study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously
      daily.

      Study visits include screening, baseline/randomization (day 1), day 15, day 28 and then
      visits every 3 months for up to 2.5 years. A month is defined as 28 days. On study day 15,
      patients will receive the second dose of either rituximab or placebo; on study day 28
      patients will begin treatment with GA therapy. Study days 15 and 28 have an acceptable window
      of +/- 4 days. Follow-up phone calls are conducted every month to assess adverse events and
      relapses. All monthly phone calls and quarterly visits must occur with a +/- 7 day window.
      Unscheduled office visits for the evaluation of symptoms suggestive of relapses will be
      scheduled as needed and may be prompted by questions elicited during the monthly safety and
      relapse assessment phone calls, or on the basis of a phone call initiated by the patient. In
      either case, those handling the phone call will interview the patient according to the
      questions described in the PDDS will be administered. If a subject reports new or worsening
      symptoms or there is a one point change in the PDDS score, an unscheduled visit will be
      necessary. The examining clinician will administer the Expanded Disability Status Scale
      (EDSS) but will be blinded to the PDDS score and type of visit (unscheduled or scheduled).
      The treating clinician will determine if the neurological change is considered a relapse
      based on EDSS scores provided by the EDSS evaluator and clinical presentation, and will make
      the decision whether or not corticosteroids should be administered for the treatment of a
      relapse. In addition, patients whose EDSS scores change sufficiently to qualify for SAD at
      either scheduled or unscheduled visits, will be asked to come in for an additional visit, 12
      weeks later, to determine whether the change is sustained.

      A sub-group of patients who provide informed consent will be enrolled in the Lumbar Puncture
      procedure. The procedure will be performed at the beginning of the study and at the 6 month
      visit. The objective will be to examine changes in CSF T and B cells and correlate them with
      evidence of disease activity by relapse, new MRI lesions and/or SAD. This procedure is
      optional for patients and will have no impact on the overall study. Patients who do decide to
      participate will sign an Addendum for Optional Procedure Consent Form The primary endpoint
      will be the number of disease-free patients, defined as patients without new lesions on brain
      MRI using the combined unique lesion approach (CUL), without sustained change in EDSS score
      over any 3-month period and without relapse. Once the last patient randomized has completed
      the final study visit for year 1 of the study, the data will be locked and an analysis
      performed on all data collected up to that point. An independent Data and Safety Monitoring
      Board (DSMB) will meet at initiation of the study and every 6 months thereafter until the end
      of the study. Members of the DSMB may unblind themselves at their discretion and the DSMB
      will include a statistician not directly involved in this study. If induction therapy fails
      to show superiority at any point, the study will be stopped.

      Standardized brain MRIs with and without gadolinium contrast will be obtained at baseline,
      and month 6, 12, 18 and 24 months (for those patients reaching this point prior to the last
      enrolled patient reaching the 12 months follow-up visit) at UCD Anschutz Medical Campus. The
      treating clinician will have access to the MRI and can discuss the results openly with
      subjects. Standardized MRIs will be obtained and interpreted locally by a physician who will
      be blinded to the subject treatment to record the endpoints described above.

      Assessments will be performed according to the schedule of events in section 4.1. Blinded
      examiners will be utilized for the EDSS, MSFC and low contrast visual acuity assessments. Lab
      results for B cell CD19+ counts will be collected by a blinded study coordinator who will
      have them reviewed on a monthly basis by a qualified member of the DSMB for safety
      assessment. But the CD19 B cell counts will not be available to the treating clinician unless
      needed for safety.

      The treating clinician and the study coordinator will manage the clinical care and study
      related procedures. Complete metabolic panel (CMP) and liver function tests (LFT) will be
      obtained once a year as Standard of Care, or more often if deemed necessary by the treating
      clinician. Complete blood counts (CBC) with differential and CD19+ labs will be collected at
      Baseline, month 1 and every 3 months from baseline to monitor B cell recovery. The examining
      clinicians and primary study coordinator will be blinded to the CD19 lab results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Disease-free Patients</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Defined as patients without new lesions on brain MRI using the combined unique lesion approach (CUL), without sustained change in EDSS score over any 3-month period and without relapse. If a clear treatment effect is sustained in the R-GA arm, defined as a ≥ 70% decrease in brain lesions on MRI, using a CUL approach, attributable to MS and ≥ 70% reduction in annual relapse rates, compared to the GA arm, the study will continue under the extension protocol. If induction therapy fails to show superiority, at any point, the study will be stopped.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Time itself is the outcome. Whenever treatment failure occurs for the first time within the follow up period of 24 months (2 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects That Fail Treatment</measure>
    <time_frame>Baseline through 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Relapse-free Subjects</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Change in neurological symptoms in association with EDSS change is defined as relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Treated for Relapse With Corticosteroid</measure>
    <time_frame>Baseline through 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Experience Multiple Relapses</measure>
    <time_frame>Baseline through 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Develop Sustained Accumulation of Disability</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Sustained accumulation of disability is defined as a 1 point change or more on the Expanded Disability Status Scale (EDSS); sustained for at least three months. Physicians assess patients' cerebral, optic, brainstem, pyramidal, sensory, cerebellar, and bowel and bladder neurological symptoms. The physician then subjectively rates the patient on the ordinal EDSS scale. The EDSS scale emphasizes ambulatory ability. The EDSS scale ranges in half integer increments from 0.0 to 10.0. Larger numbers mean more disability, with 0.0 being everything normal and 10.0 being death due to MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 24 Months on the Multiple Sclerosis Functional Composite (MSFC) Z-score</measure>
    <time_frame>Observations were recorded at baseline and 24 months.</time_frame>
    <description>The MSFC consists of Timed 25 Foot Walk Tests, 9 Hole Peg Tests, and the Paced Auditory Serial Addition Test (PASAT), administered by clinicians. The subscales are then converted into Z-scores and averaged to create the MSFC Z-score. Larger values denote improvements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Worsening One Point or More on the Patient Determined Disease Steps (PDDS) Questionnaire</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>For PDDS the patient selects an integer 0-8 according to their personal assessment of their degree of ambulatory disability. Larger numbers mean more disability, with 0 being no disability and 8 being bedridden. There is an unclassifiable category as well.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Score on Performance Scales (Baseline to 24 Months)</measure>
    <time_frame>Baseline through 24 months</time_frame>
    <description>Performance scales measures patient assessments of disability in mobility (1-6), hand (1-5), vision (1-5), fatigue (1-5), cognitive (1-5), bladder and bowel, sensory (1-5), and spasticity (1-5). The overall measure of performance is the sum of subscales, ranging from 0 to 41. Larger numbers mean more disability, with 0 being no disability and the maximum number being total disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>(Placebo and) Glatiramer Acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab and Glatiramer Acetate (R-GA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15</description>
    <arm_group_label>Rituximab and Glatiramer Acetate (R-GA)</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate</intervention_name>
    <description>20 mg injected subcutaneously daily</description>
    <arm_group_label>(Placebo and) Glatiramer Acetate</arm_group_label>
    <arm_group_label>Rituximab and Glatiramer Acetate (R-GA)</arm_group_label>
    <other_name>Copolymer 1</other_name>
    <other_name>Cop-1</other_name>
    <other_name>Copaxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.</description>
    <arm_group_label>(Placebo and) Glatiramer Acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 through 55 years of age

          -  Patients with CIS demonstrating one unifocal neurological event AND at least 2
             T2-weighted brain lesions measuring a minimum of 6mm in diameter by MRI analysis; or a
             definite diagnosis of RMS, as defined by the 2005 revised McDonald criteria(1, 2), and
             have had at least one clinically defined relapse within the past year OR one GEL on an
             MRI within the past year

          -  Women of child-bearing potential must agree to practice an acceptable method of birth
             control

          -  No evidence of progressive multifocal leukoencephalopathy (PML) or primary central
             nervous system (PCNS) lymphoma

          -  Neurologically stable with no evidence of relapse or corticosteroid treatment within
             30 days prior to randomization

          -  Subject must be able and willing to give meaningful, written informed consent prior to
             participation in the trial, in accordance with local regulatory requirements.

        Exclusion Criteria:

          -  ≥ 15 GELs on baseline MRI

          -  Treatment with interferon β, natalizumab, or fingolimod within three months of
             randomization

          -  Treatment with mitoxantrone, cyclophosphamide, or any other chemotherapeutic agent for
             MS or malignancy within 12 months of randomization

          -  Attenuated live virus vaccination within 4 weeks of randomization

          -  Positive urine and serum pregnancy test at screening or baseline visit

          -  Any prior treatment with alemtuzumab or cladribine

          -  Unable to tolerate GA

          -  History of cardiac arrhythmias, angina or any other significant cardiac abnormalities

          -  History of clinically significant chronic disease of the immune system or a known
             immunodeficiency syndrome (HIV) other than MS

          -  White Blood Cell count of less than 2.5*10^9/L or lymphocyte count below 0.4*10^9/L

          -  Positive for any evidence of past, or current, hepatitis B and/or C infection

          -  History or presence of malignancy (except basal cell carcinoma)

          -  Clinically significant alcohol or drug abuse within past two years

          -  Any medical, psychiatric or other condition that could result in a subject not being
             able to give fully informed consent, or to comply with the protocol requirements

          -  Inability to undergo MRI scans or history of hypersensitivity to gadolinium-
             diethylenetriamine penta-acetic acid (DTPA)

          -  Participation in any clinical study evaluating another investigational drug or therapy
             within three months prior to randomization

          -  Any other condition that, in the Investigator's opinion, makes the subject unsuitable
             for participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Vollmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>May 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2018</results_first_posted>
  <last_update_submitted>June 6, 2018</last_update_submitted>
  <last_update_submitted_qc>June 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Glatiramer Acetate</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Relapsing forms of Multiple Sclerosis</keyword>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glatiramer Acetate Therapy (GA)</title>
          <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
        </group>
        <group group_id="P2">
          <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
          <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glatiramer Acetate Therapy (GA)</title>
          <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
        </group>
        <group group_id="B2">
          <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
          <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.64" spread="9.15"/>
                    <measurement group_id="B2" value="36.46" spread="8.31"/>
                    <measurement group_id="B3" value="36.55" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of relapsing MS</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>RRMS/SPMS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior treatment with Tysabri</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior treatment with Tysabri (within 6 months)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale score at baseline</title>
          <description>Physicians assess patients' cerebral, optic, brainstem, pyramidal, sensory, cerebellar, and bowel and bladder neurological symptoms. The physician then subjectively rates the patient on the ordinal EDSS scale. The EDSS scale emphasizes ambulatory ability. The EDSS scale ranges in half integer increments from 0.0 to 10.0. Larger numbers mean more disability, with 0.0 being everything normal and 10.0 being death due to MS.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.63" spread="1.57"/>
                    <measurement group_id="B2" value="2.80" spread="1.78"/>
                    <measurement group_id="B3" value="2.72" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of GEL at baseline</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.54" spread="2.16"/>
                    <measurement group_id="B2" value="1.07" spread="2.53"/>
                    <measurement group_id="B3" value="0.81" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number with GEL at baseline</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Disease-free Patients</title>
        <description>Defined as patients without new lesions on brain MRI using the combined unique lesion approach (CUL), without sustained change in EDSS score over any 3-month period and without relapse. If a clear treatment effect is sustained in the R-GA arm, defined as a ≥ 70% decrease in brain lesions on MRI, using a CUL approach, attributable to MS and ≥ 70% reduction in annual relapse rates, compared to the GA arm, the study will continue under the extension protocol. If induction therapy fails to show superiority, at any point, the study will be stopped.</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>Out to the last observation for each patient within 24 months (2 years) of follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Disease-free Patients</title>
          <description>Defined as patients without new lesions on brain MRI using the combined unique lesion approach (CUL), without sustained change in EDSS score over any 3-month period and without relapse. If a clear treatment effect is sustained in the R-GA arm, defined as a ≥ 70% decrease in brain lesions on MRI, using a CUL approach, attributable to MS and ≥ 70% reduction in annual relapse rates, compared to the GA arm, the study will continue under the extension protocol. If induction therapy fails to show superiority, at any point, the study will be stopped.</description>
          <population>Out to the last observation for each patient within 24 months (2 years) of follow up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0493</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time itself is the outcome. Whenever treatment failure occurs for the first time within the follow up period of 24 months (2 years).</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>Time itself is the outcome. Whenever treatment failure occurs for the first time within the follow up period of 24 months (2 years). Exposure time varies by patient. See exposure time outcome (post hoc).</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time itself is the outcome. Whenever treatment failure occurs for the first time within the follow up period of 24 months (2 years).</description>
          <population>Time itself is the outcome. Whenever treatment failure occurs for the first time within the follow up period of 24 months (2 years). Exposure time varies by patient. See exposure time outcome (post hoc).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.29" lower_limit="5.25" upper_limit="23.39"/>
                    <measurement group_id="O2" value="23.32" lower_limit="14.64" upper_limit="NA">There was insufficient data to estimate the upper boundary of the confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0268</p_value>
            <method>Peto</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects That Fail Treatment</title>
        <time_frame>Baseline through 24 months</time_frame>
        <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Fail Treatment</title>
          <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0189</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapse-free Subjects</title>
        <description>Change in neurological symptoms in association with EDSS change is defined as relapse.</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>Out to the last observation for each patient within 24 months (2 years) of follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Relapse-free Subjects</title>
          <description>Change in neurological symptoms in association with EDSS change is defined as relapse.</description>
          <population>Out to the last observation for each patient within 24 months (2 years) of follow up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3167</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Treated for Relapse With Corticosteroid</title>
        <time_frame>Baseline through 24 months</time_frame>
        <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Treated for Relapse With Corticosteroid</title>
          <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0940</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Experience Multiple Relapses</title>
        <time_frame>Baseline through 24 months</time_frame>
        <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Experience Multiple Relapses</title>
          <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3507</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Develop Sustained Accumulation of Disability</title>
        <description>Sustained accumulation of disability is defined as a 1 point change or more on the Expanded Disability Status Scale (EDSS); sustained for at least three months. Physicians assess patients' cerebral, optic, brainstem, pyramidal, sensory, cerebellar, and bowel and bladder neurological symptoms. The physician then subjectively rates the patient on the ordinal EDSS scale. The EDSS scale emphasizes ambulatory ability. The EDSS scale ranges in half integer increments from 0.0 to 10.0. Larger numbers mean more disability, with 0.0 being everything normal and 10.0 being death due to MS.</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>At any observation within the follow up period of 24 months (2 years) out to the last observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Develop Sustained Accumulation of Disability</title>
          <description>Sustained accumulation of disability is defined as a 1 point change or more on the Expanded Disability Status Scale (EDSS); sustained for at least three months. Physicians assess patients' cerebral, optic, brainstem, pyramidal, sensory, cerebellar, and bowel and bladder neurological symptoms. The physician then subjectively rates the patient on the ordinal EDSS scale. The EDSS scale emphasizes ambulatory ability. The EDSS scale ranges in half integer increments from 0.0 to 10.0. Larger numbers mean more disability, with 0.0 being everything normal and 10.0 being death due to MS.</description>
          <population>At any observation within the follow up period of 24 months (2 years) out to the last observation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 24 Months on the Multiple Sclerosis Functional Composite (MSFC) Z-score</title>
        <description>The MSFC consists of Timed 25 Foot Walk Tests, 9 Hole Peg Tests, and the Paced Auditory Serial Addition Test (PASAT), administered by clinicians. The subscales are then converted into Z-scores and averaged to create the MSFC Z-score. Larger values denote improvements.</description>
        <time_frame>Observations were recorded at baseline and 24 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 24 Months on the Multiple Sclerosis Functional Composite (MSFC) Z-score</title>
          <description>The MSFC consists of Timed 25 Foot Walk Tests, 9 Hole Peg Tests, and the Paced Auditory Serial Addition Test (PASAT), administered by clinicians. The subscales are then converted into Z-scores and averaged to create the MSFC Z-score. Larger values denote improvements.</description>
          <units>units on a scale (MSFC Z score)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5226" lower_limit="-0.1840" upper_limit="1.2292"/>
                    <measurement group_id="O2" value="0.2630" lower_limit="-0.0882" upper_limit="0.6141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4904</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Worsening One Point or More on the Patient Determined Disease Steps (PDDS) Questionnaire</title>
        <description>For PDDS the patient selects an integer 0-8 according to their personal assessment of their degree of ambulatory disability. Larger numbers mean more disability, with 0 being no disability and 8 being bedridden. There is an unclassifiable category as well.</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Worsening One Point or More on the Patient Determined Disease Steps (PDDS) Questionnaire</title>
          <description>For PDDS the patient selects an integer 0-8 according to their personal assessment of their degree of ambulatory disability. Larger numbers mean more disability, with 0 being no disability and 8 being bedridden. There is an unclassifiable category as well.</description>
          <population>At any time within the follow up period of 24 months (2 years) out to the last observation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4073</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Score on Performance Scales (Baseline to 24 Months)</title>
        <description>Performance scales measures patient assessments of disability in mobility (1-6), hand (1-5), vision (1-5), fatigue (1-5), cognitive (1-5), bladder and bowel, sensory (1-5), and spasticity (1-5). The overall measure of performance is the sum of subscales, ranging from 0 to 41. Larger numbers mean more disability, with 0 being no disability and the maximum number being total disability.</description>
        <time_frame>Baseline through 24 months</time_frame>
        <population>At 24 months (2 years); the end of the study follow up period compared with baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate Therapy (GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Score on Performance Scales (Baseline to 24 Months)</title>
          <description>Performance scales measures patient assessments of disability in mobility (1-6), hand (1-5), vision (1-5), fatigue (1-5), cognitive (1-5), bladder and bowel, sensory (1-5), and spasticity (1-5). The overall measure of performance is the sum of subscales, ranging from 0 to 41. Larger numbers mean more disability, with 0 being no disability and the maximum number being total disability.</description>
          <population>At 24 months (2 years); the end of the study follow up period compared with baseline.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1466" lower_limit="-1.4328" upper_limit="1.726"/>
                    <measurement group_id="O2" value="0.3477" lower_limit="-1.6109" upper_limit="2.3062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8677</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Exposure Time</title>
        <description>Values represent mean duration of treatment.</description>
        <time_frame>Measured in three month intervals from baseline to end of study.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>(Placebo and) Glatiramer Acetate</title>
            <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily
Placebo: Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab and Glatiramer Acetate (R-GA)</title>
            <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
          </group>
        </group_list>
        <measure>
          <title>Exposure Time</title>
          <description>Values represent mean duration of treatment.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.517" spread="0.766"/>
                    <measurement group_id="O2" value="1.704" spread="0.830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Mean difference between treatment groups.</non_inferiority_desc>
            <p_value>0.3974</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Within 24 months (2 years) of follow up. Exposure time varied by patient.</time_frame>
      <desc>Out to the last observation for each patient within 24 months (2 years) of follow up. Exposure time varied by patient. See exposure time outcome (post hoc).</desc>
      <group_list>
        <group group_id="E1">
          <title>Glatiramer Acetate Therapy (GA)</title>
          <description>Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
        </group>
        <group group_id="E2">
          <title>Rituximab + Glatiramer Acetate Therapy (R-GA)</title>
          <description>Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
Rituximab: intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate: 20 mg injected subcutaneously daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>FDA guidlines</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Relapse related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological Condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>FDA guidlines</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Issues</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion-related reaction</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" events="42" subjects_affected="19" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E2" events="28" subjects_affected="17" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="20" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" events="35" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Injection-site reaction</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Backpain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stefan Sillau</name_or_title>
      <organization>University of Colorado</organization>
      <phone>303-724-8657</phone>
      <email>stefan.sillau@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

